Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Share-based Compensation (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Share-based Compensation readings, the most recent being $4.5 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 55.23% to $4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.6 million, a 132.76% increase, with the full-year FY2025 number at $13.6 million, up 132.76% from a year prior.
  • Share-based Compensation hit $4.5 million in Q4 2025 for Avalo Therapeutics, up from $3.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $5.3 million in Q1 2022 to a low of $471000.0 in Q2 2024.
  • Median Share-based Compensation over the past 5 years was $1.6 million (2021), compared with a mean of $1.9 million.
  • Biggest five-year swings in Share-based Compensation: tumbled 83.9% in 2023 and later surged 477.07% in 2025.
  • Avalo Therapeutics' Share-based Compensation stood at $1.9 million in 2021, then tumbled by 55.44% to $843000.0 in 2022, then dropped by 7.95% to $776000.0 in 2023, then surged by 274.23% to $2.9 million in 2024, then skyrocketed by 55.23% to $4.5 million in 2025.
  • The last three reported values for Share-based Compensation were $4.5 million (Q4 2025), $3.2 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.